

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignina 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/202,791	12/22/1998	KOUJI MATSUSHIMA	350292000500	3409
25225 7:	590 06/18/2003			
	& FOERSTER LLP	EXAMINER		
SUITE 500	CENTRE DRIVE	WARE, DEBORAH K		
SAN DIEGO, O	CA 92130-2332		ART UNIT	PAPER NUMBER
			1651	つつつ
			DATE MAILED: 06/18/2003	UT

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/202,791

Applicant(s)

Matsushima et al.

Examiner

Deborah Ware

1651



	The M	AILING DATE of this co	mmunication appears	on the cover s	heet with	the correspondence address	
	for Reply		•			!	
THE	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET THE MAILING DATE OF THIS COMMUNICATION.						
		may be available under the provisi communication.	ions of 37 CFR 1.136 (a). In	no event, however,	may a reply b	be timely filed after SIX (6) MONTHS from the	
- If the p - If NO p - Failure - Any re	period for reply period for reply to reply within eply received b	ly specified above is less than thir	im statutory period will apply a reply will, by statute, cause th nths after the mailing date of t	and will expire SIX (6 he application to beco	3) MONTHS frome ABANDO		
Status						!	
1) 💢	Responsi	sive to communication(s) filed on <i>Jan 7, 20</i>	103			
2a) 💢	This acti	ion is FINAL .	2b) ☐ This act	tion is non-fina	al.	!	
3) 🗆	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.						
	ition of Cla					ļ	
4) 💢	Claim(s)	16-29 and 31-44				is/are pending in the application.	
4	4a) Of the	above, claim(s)				is/are withdrawn from consideration.	
5) 🗆	Claim(s)		·			is/are allowed.	
6) 💢	Claim(s)	16-29 and 31-44				is/are rejected.	
7) 🗆	Claim(s)				•	is/are objected to.	
8) 🗆	Claims _			ar	e subject	to restriction and/or election requirement.	
Applica	ation Pape	ırs					
9) 🗆	The spec	cification is objected to	by the Examiner.				
10)	The drav	wing(s) filed on	is/are	; a) 🗌 accept	ed or b)[\square objected to by the Examiner.	
	Applicar	nt may not request that	any objection to the d	drawing(s) be h	eld in abe [,]	yance. See 37 CFR 1.85(a).	
11)	The prop	osed drawing correcti	on filed on	is	s: a)□ a	approved b) \square disapproved by the Examiner.	
	If approved, corrected drawings are required in reply to this Office action.						
12)	The oath	n or declaration is objec	cted to by the Exami	iner.			
Priority	under 35	5 U.S.C. §§ 119 and 1	20				
13)	Acknow	ledgement is made of	a claim for foreign pr	riority under 3	5 U.S.C.	§ 119(a)-(d) or (f).	
a) 🗆	a) All b) Some* c) None of:						
	1. Certified copies of the priority documents have been received.						
	2. Cer	rtified copies of the pri-	ority documents hav	re been receive	ed in App	olication No	
		application from ti	ne international Bure	au (PCT Rule '	17.2(a)).	eceived in this National Stage	
		tached detailed Office		-		•	
14) 📙	_	ledgement is made of					
a) ∟ 15) 🔲		anslation of the foreign					
		ledgement is made of a	a claim for domestic	priority under	35 0.5.0	J. 33 120 and/or 121.	
Attachm 1) No		ences Cited (PTO-892)		4) Interview S	ummarv (PTC	O-413) Paper No(s).	
		person's Patent Drawing Review	(PTO-948)			t Application (PTO-152)	
_	3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 6) Cher:						

Art Unit: 1651

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deborah K. Ware whose telephone number is (703) 308-4245. The examiner can normally be reached on Mondays to Fridays from 9:30AM to 6:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn, can be reached on (703) 308-4743. The fax phone number for the organization where this application or proceeding is assigned is (703) 305-3592.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Deborah K. Ware

June 13, 2003

Application/Control Number: 09/202,791 Page 2

Art Unit: 1651

Claims 16-29 and 31-44 are presented for reconsideration on the merits.

The amendment filed January 7, 2003, has been received and entered.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

- 1. Claims 16-29 and 31-44 remain rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention for reasons of record.
- 2. The argument filed January 7, 2003, that "indirect causes" is definite is noted. However, limitations from the specification can not be read into the claims. There are many indirect causes which may or may not be intended within the metes and bounds of the claimed subject matter. Thus, the rejection is maintained.
- 3. Claims 16-29 and 31-44 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Folkesson et al., cited of record, in view of Slotman cited of record in the last office action of July 2, 2002, note pages 4-5.

The argument Folkesson is limited to direct cause is noted, however, indirect causes as disclosed by Slotman would have been expected to be treatable as well. Essentially a disease is an effect which would have been expected to be treated and one of skill would have not reason to not expect successful results from Folksesson based merely on the cause of the disease as alleged by Applicants. Wherein Slotman is lacking, if at all, Folkesson clearly teaches the active ingredient, IL-8 antibody. The IL-8 is clearly disclosed to be useful for a wide variety of diseases

Application/Control Number: 09/202,791

Art Unit: 1651

whether they be indirect or direct. Also the specific indirect diseases Applicants argue are not an absolute requirement of the claims. Slotman is combined with Folkesson wherein it is disclosed that neutralization of IL-8 is critical for appropriate treatment for lung injury. Furthermore, acute lung injury would have been expected to be treated using the cited combination of treatment because Folkesson recognized at the time the Applicants' filed their invention that IL-8 needs to be neutralized and it is known therapy. Therefore, the claims remain prima facie obvious over the cited prior art.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

No claims are allowed.

PAVID M. NAFF PRIMARY EXAMINED ART UNIT 1/6 Page 3